← Leaderboards
Michael W. Konstan
Case Western Reserve University
$52,389,820
Attributed
$52,389,820
Total exposure
21
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $12.9M · FY2005–20$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$52,389,820 · 21
By mechanism
UL1$43,337,231 · 2
KL2$4,451,252 · 1
P30$1,510,849 · 2
TL1$1,135,549 · 1
P01$1,071,577 · 1
M01$466,355 · 13
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Thomas C. Chelimsky$7,147,290
- Mitchell L Drumm$12,943,746
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCystic FibrosisHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationTranslationsClinical TrialsRespiratory Disorder ChemotherapyResourcesLaboratoriesDatabasesPharmacokineticsInhalation Drug AdministrationTranslational ResearchBasic ScienceOperationDiagnostic Respiratory LavageMalignant NeoplasmsResearch PersonnelCommunitiesClinical SciencesDesignPreparationPrograms
Grant awards (49)
Clinical and Translational Science Collaborative of Cleveland$6,722,040
UL1 · FY2020 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$140,205
UL1 · FY2020 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$7,746,299
UL1 · FY2019 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$8,987,199
UL1 · FY2018 · TR · contact PI
Core C - Clinical Studies$362,794
P01 · FY2018 · HL · contact PI
Core C - Clinical Studies$362,794
P01 · FY2017 · HL · contact PI
Clinical and Translational Science Collaborative of Cleveland$9,774,822
UL1 · FY2016 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$2,223,126
KL2 · FY2016 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$570,483
TL1 · FY2016 · TR · contact PI
Core C - Clinical Studies$345,989
P01 · FY2016 · HL · contact PI
Clinical and Translational Science Collaborative of Cleveland$9,966,666
UL1 · FY2015 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$2,228,126
KL2 · FY2015 · TR · contact PI
Clinical and Translational Science Collaborative of Cleveland$565,066
TL1 · FY2015 · TR · contact PI
Research Career Development in Child Health$214,916
K12 · FY2012 · HD · contact PI
Clinical Studies$280,554
P30 · FY2011 · DK · contact PI
Research Career Development in Child Health$202,091
K12 · FY2011 · HD · contact PI
Clinical Studies$281,279
P30 · FY2010 · DK · contact PI
Clinical Studies$312,167
P30 · FY2009 · DK · contact PI
Clinical Studies$274,050
P30 · FY2008 · DK · contact PI
Clinical Studies$214,163
P30 · FY2007 · DK · contact PI
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS$47,829
M01 · FY2006 · RR · contact PI
ORAL THERACLEC-TOTAL IN CF PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY$154,509
M01 · FY2005 · RR
BIIL284BS IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$10,053
M01 · FY2005 · RR
TOBRAMYCIN FOR INHALATION (TOBI) IN YOUNG CHILDREN WITH CYSTIC FIBROSIS$529
M01 · FY2005 · RR
Fat and protein absorption in cystic fibrosis pts with pancreatic insufficiency$72,345
M01 · FY2004 · RR
Oral TheraCLEC-Total in adult and pediatric subjects with cystic fibrosis$62,062
M01 · FY2004 · RR
BIIL284BS in adult and pediatric cystic fibrosis patients$30,113
M01 · FY2004 · RR
Neutrophil imaging of the lung for characterizing pulmonary infection in CF pts$12,119
M01 · FY2004 · RR
Free elastase concentration in BAL fluid in cystic fibrosis$0
M01 · FY2002 · RR
INS365 in adult &pediatric cystic fibrosis$0
M01 · FY2002 · RR
LUNG SPECIFIC BIOEFFICACY OF ORAL DMP 777 IN ADULTS W/ CF$0
M01 · FY2002 · RR
CPX (ORAL, MULTIDOSE) IN ADULTS W/ MILD TO MODERATELY SEVERE CYSTIC F$0
M01 · FY2002 · RR
Lower airway deposit of inhaled tobramycin in cystic fib$0
M01 · FY2002 · RR
IB367 in adult patients with cystic fibrosis$0
M01 · FY2002 · RR
LUNG SPECIFIC BIOEFFICACY OF ORAL DMP 777 IN ADULTS W/ CF$0
M01 · FY2001 · RR
Lower airway deposit of inhaled tobramycin in cystic fib$0
M01 · FY2001 · RR
IB367 in adult patients with cystic fibrosis$0
M01 · FY2001 · RR
Free elastase concentration in BAL fluid in cystic fibrosis$0
M01 · FY2001 · RR
INS365 in adult &pediatric cystic fibrosis$0
M01 · FY2001 · RR
CPX (ORAL, MULTIDOSE) IN ADULTS W/ MILD TO MODERATELY SEVERE CYSTIC F$0
M01 · FY2001 · RR
PROLASTIN AEROSOL THERAPY IN PATIENTS WITH CYSTIC FIBROSIS$148,636
P30 · FY2000 · DK
CPX IN ADULT PATIENTS WITH MILD CYSTIC FIBROSIS$19,199
M01 · FY2000 · RR
CPX (ORAL, MULTIDOSE) IN ADULTS W/ MILD TO MODERATELY SEVERE CYSTIC F$19,199
M01 · FY2000 · RR
LUNG SPECIFIC BIOEFFICACY OF ORAL DMP 777 IN ADULTS W/ CF$19,199
M01 · FY2000 · RR
DMP777 IN ADULT PATIENTS 18 YRS OF AGE AND OLDER WITH CYSTIC FIBROSIS$19,199
M01 · FY2000 · RR
INS365 in adult &pediatric cystic fibrosis$0
M01 · FY2000 · RR
Lower airway deposit of inhaled tobramycin in cystic fib$0
M01 · FY2000 · RR
IB367 in adult patients with cystic fibrosis$0
M01 · FY2000 · RR
Free elastase concentration in BAL fluid in cystic fibrosis$0
M01 · FY2000 · RR